The phase III ECHELON‐2 compared BV + cyclophosphamide, doxorubicin, and prednisone (CHP) vs. CHOP in patients with ALCL or other CD30‐positive PTCL with > 10% CD30 expression [143]. This evidence concerns the gene TNFRSF8 and anaplastic large cell lymphoma.